DrugPatentWatch Database Preview
Biologic Drugs With Dosage Form: VIAL; INTRAVENOUS
» See Plans and Pricing
Details for Dosage Type: VIAL; INTRAVENOUS
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | The Regents of the University of California (Oakland, CA) | 2035-02-24 | RX | search | |
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | CAVA HEALTHCARE INC. (CA) | 2033-11-20 | RX | search | |
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | Spectrum Dynamics LLC (Orangeburg, NY) | 2020-08-21 | RX | search | |
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | AbbVie, Inc. (North Chicago, IL) | 2027-11-30 | RX | search | |
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) | 2031-08-05 | RX | search | |
Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | Start Trial | AbbVie Inc. (North Chicago, IL) | 2027-11-30 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |